Celea Therapeutics has raised $180 million to develop a new treatment for idiopathic pulmonary fibrosis (IPF), a serious disease that causes progressive scarring of the lungs.
The company is backed by PureTech, the biotech incubator behind several other well-known startups. According to Endpoints News, Celea hopes to follow the path of its "siblings" Seaport Therapeutics and Karuna Therapeutics, two other PureTech-spawned companies.
The new funding comes from major backers. According to BioPharma Dive, investors include RA Capital and Leaps by Bayer, among others.
What is Celea trying to make? According to BioPharma Dive, the company says it is developing an improved version of Roche's Esbriet, an existing IPF medicine. In other words, Celea is betting it can build a better drug in a category that already has an established treatment.
IPF is a difficult condition with limited options, so companies that can offer more effective or better-tolerated therapies stand to make a meaningful difference for patients — and to capture a valuable market. The $180 million war chest gives Celea the runway to test whether its version can outperform what is already on pharmacy shelves.
Why it matters: A large, well-funded push to improve on an existing lung-fibrosis drug could expand and upgrade treatment options for a disease that remains hard to manage.